Zhida Liu

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 7

Top Topics

Dendritic Cells

Tyrosine Kinase

Immune Response

Top Venues

Nature communications

Science immunology

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Chuanhui Han, Victoria Godfrey, Zhida Liu, Yanfei Han, Longchao Liu, Hua Peng, Ralph R Weichselbaum, Hasan Zaki, Yang-Xin Fu
The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. Science immunology 6 (59) (2022)
Yuzhu Hou, Hua Laura Liang, Xinshuang Yu, Zhida Liu, Xuezhi Cao, Enyu Rao, Xiaona Huang, Liangliang Wang, Lei Li, Jason Bugno, Yanbin Fu, Steven J Chmura, Wenjun Wu, Sean Z Luo, Wenxin Zheng, Ainhoa Arina, Jessica M S Jutzy, Anne R McCall, Everett E Vokes, Sean P Pitroda, Yang-Xin Fu, Ralph R Weichselbaum
Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Science translational medicine 13 (582) (2021)
Lang Rao, Lei Wu, Zhida Liu, Rui Tian, Guocan Yu, Zijian Zhou, Kuikun Yang, Hong-Gang Xiong, Anli Zhang, Guang-Tao Yu, Wenjing Sun, Han Xu, Jingya Guo, Andrew Li, Hongmin Chen, Zhi-Jun Sun, Yang-Xin Fu, Xiaoyuan Shawn Chen
Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. Nature communications 11 (1) (2020)
Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng
Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature communications 11 (1) (2020)
Zhida Liu, Chuanhui Han, Chunbo Dong, Aijun Shen, Eric J Hsu, Zhenhua Ren, Changzheng Lu, Longchao Liu, Anli Zhang, Casey Timmerman, Yang Pu, Yang Wang, Mingyi Chen, Jian Qiao, Yang-Xin Fu
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science immunology 4 (38) (2020)
Xiaoguang Li, Zhida Liu, Anli Zhang, Chuanhui Han, Aijun Shen, Lingxiang Jiang, David A Boothman, Jian Qiao, Yang Wang, Xiumei Huang, Yang-Xin Fu
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nature communications 10 (1) (2019)
Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature communications 10 (1) (2019)